Our broad goals include delineating how the cell division cycle is regulated, determining how cancer cells derail cell cycle regulatory pathways, and ultimately using this information for diagnosing and treating human cancers. We propose to focus our efforts on the Cdc25A protein phosphatase as this enzyme is a key regulator of the cell division cycle in mammals and is overproduced in a wide range of human tumors. Stable cell lines and mouse colonies will be generated that enable Cdc25A regulation to be studied in cells and living mice using molecular imaging technologies. In particular, cell lines that inducibly express a fusion protein between human Cdc25A and firefly luciferase (Cdc25A-FLuc) will be used in a high throughput screen to identify the serine/threonine protein phosphatase holoenzymes that regulate the stability of Cdc25A in vivo. In principal the proteins identified in this study could provide novel targets for imaging agents and therapeutic intervention in cancer treatment. In addition, knock-in mice will be generated that express a fusion protein between endogenous Cdc25A and click beetle red luciferase (Cdc25A-CBRLuc) from the Cdc25A locus. In this way endogenous Cdc25A protein levels can be monitored non-invasively and repetitively in living mice under steady state conditions and in response to DMAdamaging agents and drugs targeting cell cycle checkpoints. In addition, molecular imaging strategies will be applied to mouse models of breast cancer to validate target specificity of rational anti-cancer therapeutic regimens in combination therapies. The reagents and results obtained in these studies will be useful in future clinical trials that combine DNA damaging agents with novel Chk1 inhibitors or novel checkpoint abrogators. The proposed studies are expected to enhance our understanding of basic principles of cell cycle control in mammals and may impact future therapeutic strategies for cancer treatment.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA094056-11
Application #
8233023
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2011-01-01
Budget End
2011-12-31
Support Year
11
Fiscal Year
2011
Total Cost
$258,040
Indirect Cost
Name
Washington University
Department
Type
DUNS #
068552207
City
Saint Louis
State
MO
Country
United States
Zip Code
63130
Miller, Jessica; Wang, Steven T; Orukari, Inema et al. (2018) Perfusion-based fluorescence imaging method delineates diverse organs and identifies multifocal tumors using generic near-infrared molecular probes. J Biophotonics 11:e201700232
Zacharias, Niki; Lee, Jaehyuk; Ramachandran, Sumankalai et al. (2018) Androgen Receptor Signaling in Castration-Resistant Prostate Cancer Alters Hyperpolarized Pyruvate to Lactate Conversion and Lactate Levels In Vivo. Mol Imaging Biol :
Cherian, Mathew A; Olson, Sydney; Sundaramoorthi, Hemalatha et al. (2018) An activating mutation of interferon regulatory factor 4 (IRF4) in adult T-cell leukemia. J Biol Chem 293:6844-6858
Hövener, Jan-Bernd; Pravdivtsev, Andrey N; Kidd, Bryce et al. (2018) Parahydrogen-Based Hyperpolarization for Biomedicine. Angew Chem Int Ed Engl 57:11140-11162
Bauerle, Kevin T; Hutson, Irina; Scheller, Erica L et al. (2018) Glucocorticoid Receptor Signaling Is Not Required for In Vivo Adipogenesis. Endocrinology 159:2050-2061
Prudner, Bethany Cheree; Sun, Fangdi; Kremer, Jeffrey Charles et al. (2018) Amino Acid Uptake Measured by [18F]AFETP Increases in Response to Arginine Starvation in ASS1-Deficient Sarcomas. Theranostics 8:2107-2116
Meinerz, Kelsey; Beeman, Scott C; Duan, Chong et al. (2018) Bayesian Modeling of NMR Data: Quantifying Longitudinal Relaxation in Vivo, and in Vitro with a Tissue-Water-Relaxation Mimic (Crosslinked Bovine Serum Albumin). Appl Magn Reson 49:3-24
Zheleznyak, Alexander; Shokeen, Monica; Achilefu, Samuel (2018) Nanotherapeutics for multiple myeloma. Wiley Interdiscip Rev Nanomed Nanobiotechnol 10:e1526
Choi, Jaebok; Cooper, Matthew L; Staser, Karl et al. (2018) Baricitinib-induced blockade of interferon gamma receptor and interleukin-6 receptor for the prevention and treatment of graft-versus-host disease. Leukemia 32:2483-2494
Kotagiri, Nalinikanth; Cooper, Matthew L; Rettig, Michael et al. (2018) Radionuclides transform chemotherapeutics into phototherapeutics for precise treatment of disseminated cancer. Nat Commun 9:275

Showing the most recent 10 out of 283 publications